Related Articles
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients
Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era
Phase 2 study of CHOP‑R‑14 followed by 90Y‑ibritumomab tiuxetan in patients with previously untreated diffuse large B‑cell lymphoma
Effects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B‑cell lymphoma